Certara (CERT) has been reclassified out of several Russell 1000 and Midcap indexes and into the Russell 2000 and Russell 2000 Value benchmarks, a change that can reshape how index-linked investors trade the stock.
See our latest analysis for Certara.
Recent trading suggests interest in Certara is picking up in the short term, with a 1 month share price return of 24.24% and a 3 month share price return of 28.84%. This comes even though the 1 year total shareholder return is down 38.48% and the 5 year total shareholder return is down 74.17%.
If the index reshuffle has you rethinking your exposure, it can be helpful to see what else is moving and compare Certara with other healthcare focused AI plays via the 40 healthcare AI stocks
With Certara trading at US$6.97 and sitting at an estimated 33% discount to intrinsic value, investors are left with a key question: is this still an overlooked opportunity, or is the market already baking in future growth?
Most Popular Narrative: 7% Undervalued
At a last close of $6.97, the most followed narrative on Certara pegs fair value at $7.48, leaving a modest valuation gap that hinges on how investors view its biosimulation and model informed drug development opportunity.
The recent qualification of Certara's Simcyp platform by the European Medicines Agency sets it apart as the only PBPK modeling tool with such approval, likely to increase customer adoption among global pharma companies seeking regulatory certainty and speed for their drug approvals, supporting future revenue growth.
Read the complete narrative. Read the complete narrative.
Want to see what sits underneath that modest discount to fair value? The narrative leans on steady revenue build, margin uplift and a rich earnings multiple to justify today’s pricing gap.
Result: Fair Value of $7.48 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, Certara’s story can change quickly if pharma customers pull back on software adoption or large clients trim R&D budgets, which could pressure bookings and profitability.
Find out about the key risks to this Certara narrative.
Another View: Certara Looks Expensive On Sales
There is a twist to Certara’s valuation story. While some see upside to fair value, the stock trades on a P/S ratio of 2.6x compared with 2.5x for the broader US Healthcare Services group and 2.3x for peers, versus a fair ratio of 1.4x that the market could move toward.
If sales based pricing is closer to the mark than discounted cash flows or narrative driven targets, that gap could signal more valuation risk than opportunity for Certara at current levels, especially for investors who anchor on relative multiples rather than long term projections. See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
If the mixed views on Certara’s valuation leave you on the fence, it makes sense to move quickly and test the assumptions against your own research. To see what optimism in the market is based on, take a closer look at the 2 key rewards.
Looking for more investment ideas beyond Certara?
If Certara has caught your attention, do not stop there. Broadening your watchlist with other ideas can help you spot opportunities you might otherwise miss.
- Target potential mispricing by scanning for quality stocks trading below estimated value using the thoughtfully curated 44 high quality undervalued stocks.
- Prioritize resilience by focusing on companies with stronger balance sheets and fundamentals through the solid balance sheet and fundamentals stocks screener (47 results).
- Spot under-the-radar opportunities by reviewing the screener containing 18 high quality undiscovered gems before others start paying attention.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com